ROVI obtains second place in a global sustainability rating

ROVI has obtained second place among 360 international pharmaceutical companies in the sustainability rating drawn up by Sustainalytics, a global leader in the evaluation of the Corporate Social Responsibility and Corporate Governance


ROVI participated voluntarily in this rating, which measures the sustainability of companies based on criteria such as corporate governance, business ethics, product management, bribery and corruption and human capital, among others. Thus, the ESG (Environmental, Social and Governance) rating is calculated and furnishes the basis for the company ratings.

In this rating, ROVI obtained the second best rating in the pharmaceutical company category and the 30th of a total of 750 companies in the sector, which includes biotechnology companies and pharmaceutical and health equipment laboratories.

We are proud to see that the management of ROVI, a day-to-day reflection of the company’s values, has received such a high sustainability rating.

No votes yet
 
Related
ROVI reports operating revenue growth of 24% and EBITDA growth of 25% • Operating revenue increased by 24% to 575.5 million euros driven...
3 min
04/11/2022
On his visit to the plant, which is ready to start production as soon as the authorisation from the Spanish Agency of Medicines and...
4 min
24/10/2022
Glicopepton Biotech founded to produce compounds of high technological value   · ROVI, Càrniques Celrà and Grupo Costa announce...
3 min
04/10/2022